Curated News
By: NewsRamp Editorial Staff
May 28, 2025
NanoViricides to Present at BIO International Convention 2025, Showcasing Antiviral Drug Pipeline
TLDR
- NanoViricides to present NV-387 at BIO International Convention, showcasing superior antiviral technology for potential first empiric therapy.
- NanoViricides' nanoviricide platform enables oral delivery, drug rescue, and tissue-specific targeting, revolutionizing antiviral therapy with NV-387.
- NanoViricides' NV-387 aims to transform viral treatment, potentially improving global health outcomes by offering superior antiviral efficacy and novel drug delivery methods.
- NanoViricides' presentation at BIO International Convention offers insight into cutting-edge antiviral technology, promising a new era in viral treatment methods.
Impact - Why it Matters
This news matters as it highlights NanoViricides' innovative approach to antiviral therapy, particularly with the development of NV-387 for various viral infections. The presentation at the BIO International Convention signifies the company's commitment to advancing treatments that could potentially revolutionize viral care and provide new solutions for respiratory infections like COVID-19.
Summary
NanoViricides, Inc. (NYSE American: NNVC) will present at the BIO International Convention 2025 to discuss its drug pipeline and licensing-ready platform technologies. The focus will be on NV-387, a broad-spectrum antiviral nearing Phase II trials for MPOX and demonstrating efficacy against RSV, Influenza A, and coronaviruses. The company will also showcase candidates targeting herpesviruses and HIV, along with its nanoviricide platform.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, NanoViricides to Present at BIO International Convention 2025, Showcasing Antiviral Drug Pipeline
